Ginkgo Bioworks Holdings Inc (DNA)
7.285
-1.32
(-15.29%)
USD |
NYSE |
Nov 14, 16:00
7.37
+0.08
(+1.17%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Enterprise Value: -252.42M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -252.42M |
| November 12, 2024 | -264.09M |
| November 11, 2024 | -243.53M |
| November 08, 2024 | -258.53M |
| November 07, 2024 | -264.65M |
| November 06, 2024 | -268.54M |
| November 05, 2024 | -286.32M |
| November 04, 2024 | -306.33M |
| November 01, 2024 | -299.66M |
| October 31, 2024 | -306.88M |
| October 30, 2024 | -294.66M |
| October 29, 2024 | -285.21M |
| October 28, 2024 | -270.76M |
| October 25, 2024 | -276.87M |
| October 24, 2024 | -289.10M |
| October 23, 2024 | -227.41M |
| October 22, 2024 | -209.07M |
| October 21, 2024 | -234.63M |
| October 18, 2024 | -236.86M |
| October 17, 2024 | -264.65M |
| October 16, 2024 | -270.76M |
| October 15, 2024 | -297.43M |
| October 14, 2024 | -325.78M |
| October 11, 2024 | -323.00M |
| October 10, 2024 | -331.34M |
| Date | Value |
|---|---|
| October 09, 2024 | -290.77M |
| October 08, 2024 | -266.87M |
| October 07, 2024 | -265.76M |
| October 04, 2024 | -267.42M |
| October 03, 2024 | -279.09M |
| October 02, 2024 | -301.88M |
| October 01, 2024 | -307.99M |
| September 30, 2024 | -277.43M |
| September 27, 2024 | -280.76M |
| September 26, 2024 | -302.44M |
| September 25, 2024 | -299.10M |
| September 24, 2024 | -281.87M |
| September 23, 2024 | -295.21M |
| September 20, 2024 | -285.21M |
| September 19, 2024 | -268.54M |
| September 18, 2024 | -318.55M |
| September 17, 2024 | -351.90M |
| September 16, 2024 | -384.13M |
| September 13, 2024 | -379.13M |
| September 12, 2024 | -381.91M |
| September 11, 2024 | -383.58M |
| September 10, 2024 | -403.58M |
| September 09, 2024 | -432.48M |
| September 06, 2024 | -416.37M |
| September 05, 2024 | -389.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-432.48M
Minimum
Sep 09 2024
788.49B
Maximum
Sep 27 2021
11.79B
Average
2.381B
Median
Enterprise Value Benchmarks
| Boston Scientific Corp | 139.46B |
| UnitedHealth Group Inc | 608.37B |
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -217.18M |
| Revenue (Quarterly) | 56.21M |
| Total Expenses (Quarterly) | 214.23M |
| EPS Diluted (Quarterly) | -4.40 |
| Gross Profit Margin (Quarterly) | 75.59% |
| Profit Margin (Quarterly) | -386.4% |
| Earnings Yield | -252.6% |
| Normalized Earnings Yield | -188.25 |